Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ALPI | P09923 | 1/20 | 0.68 |
| ▸ | ALPG | P10696 | 1/20 | 0.68 |
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.68 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.66 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.64 |
| ▸ | RRM1 | P23921 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | KLF5 | Q13887 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 7/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767408 | 0.81 | SPHK1 (0.73) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL1639418 | 0.81 | SPHK1 (0.73) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL1639416 | 0.81 | SPHK1 (0.73) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL800974 | 0.80 | PAX8 (1.00) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL1679411 | 0.80 | PAX8 (1.00) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL16713131 | 0.80 | PAX8 (1.00) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL29414666 | 0.80 | PAX8 (1.00) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL2847708 | 0.79 | MEN1 (0.85) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL683715 | 0.79 | MEN1 (0.85) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL21649964 | 0.79 | PAX8 (0.69) | MEN1KMT2APOLBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9895363-B2 | Methods for modulating function of proliferating cell nuclear antigen (PCNA) and treating cancer with PCNA-targeting compounds | UNIVERSITY OF CINCINNATI (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895363-B2 | Methods for modulating function of proliferating cell nuclear antigen (PCNA) and treating cancer with PCNA-targeting compounds | UNIVERSITY OF CINCINNATI (US) | 2018-02-20 | — | — | US | disclosed |
| US-20140018385-A1 | Identification Of PCNA Targeting Compounds For Cancer Therapy And PCNA Function Regulation | UNIVERSITY OF CINCINNATI (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018385-A1 | Identification Of PCNA Targeting Compounds For Cancer Therapy And PCNA Function Regulation | UNIVERSITY OF CINCINNATI (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2012033938-A2 | IDENTIFICATION OF PCNA TARGETING COMPOUNDS FOR CANCER THERAPY AND PCNA FUNCTION REGULATION | UNIVERSITY OF CINCINNATI (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018385-A1 | Identification Of PCNA Targeting Compounds For Cancer Therapy And PCNA Function Regulation | PCNA, MKI67, PCLAF | MEN1 2771/4885KMT2A 2730/4885POLB 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.